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SHORT COMMUNICATION
Analysis of p16 gene deletion and point mutation in breast carcinoma
B Quesnell"2, P Fenaux'"2, N Philippe', J Fournier3, J Bonneterre3, C Preudhommel 4 and JP
Peyrat3
'U124 Inserm Institut de Recherches sur le Cancer, Lille; 2Service des Maladies du Sang, CHU Lille; 'Centre Oscar Lambret,
Lille; 4Laboratoire d'Hematologie A, CHU Lille, France.
Summary We looked for p16 gene deletion by Southern analysis and p16 gene point mutation by single-
stranded conformation polymorphism (SSCP) analysis and direct sequencing of DNA from fresh tumour
samples of 35 and 33 breast carcinomas respectively. No homozygous p16 gene deletion was found in any
case. A missense point mutation of the p16 gene was found in only one patient. This point mutation was
absent from the patient's lymphocytes, ruling out a polymorphism or a germline mutation. These findings
suggest that p16 gene alterations are rarely observed in breast carcinoma.
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Progress through the cell cycle appears to be regulated by a
number of cyclin-dependent protein kinases, the CdKs. The
p16 protein is an inhibitor of CdK 4, encoded by a gene
(multiple tumour-suppressor 1, MTS 1, CDKN2 or p16 gene)
localised on chromosome 9p2l (Serrano et al., 1993; Kamb et
al., 1994; Nobori et al., 1994). By binding to and inhibiting
CdK 4, p16 could suppress cell division in a similar fashion
to p21, whose synthesis is stimulated by p53 and which
inhibits other CdKs (Pines, 1994). The p16 gene is therefore
considered as a potential tumour-suppressor gene (Serrano et
al., 1993; Kamb et al., 1994; Nobori et al., 1994).
Deletion and loss of heterozygosity of 9p21 is seen in a
large variety of tumours, including malignant melanoma,
glioma, lung cancer, bladder, pancreatic and renal cancer and
acute lymphoblastic leukaemia, and homozygous deletion of
the p16 gene has recently been found in 30-85% ofcell lines
established from those tumours (Caldas et al., 1994; Kamb et
al., 1994; Nobori et al., 1994; Quesnel et al., 1995). Further-
more, melanoma and pancreatic cell lines frequently carry
nonsense, missense or frameshift mutations of the p16 gene,
predominantly in exon 2 (Kamb et al., 1994). However, in
fresh solid tumours the incidence of homozygous deletion of
the p16 gene seems to be lower (10-20%), and point muta-
tions very rare except in melanoma, pancreatic carcinoma
and oesophageal carcinoma (Caldas et al., 1994; Mori et al.,
1994; Spruck et al., 1994). Germline p16 mutations may also
be associated with familial melanoma (Hussussian et al.,
1994).
Although loss of heterozygosity in the 9p region appears to
be quite rare in breast carcinoma, homozygous deletion of
the p16 gene was observed in six of ten and two offive breast
carcinoma cell lines in two studies (Kamb et al., 1994; Xu et
al., 1994). The second study found no homozygous deletion
and no point mutation of the p16 gene in 5 and 37 primary
breast carcinoma samples respectively.
In this study, we looked for homozygous deletion and
rearrangements of the p16 gene by Southern blot analysis in
35 primary breast carcinoma samples. In 33 of those samples,
we also looked for point mutations of the p16 gene by
polymerase chain reaction-single stranded conformation
polymorphism (PCR-SSCP) analysis of exons 1 and 2 of the
gene (which correspond to 97% of the total coding region).
Materials and methods
Materials
DNA obtained from surgically resected tumours of 35 cases
of breast carcinoma were studied by Southern blot. Thirty-
three of those cases were also studied by SSCP analysis of
exons 1 and 2 of the p16 gene, which correspond to 97% of
the coding region. The tumour size was < 1 cm in six
patients, 1-3 cm in 23 patients, >3 cm in six patients.
Lymph nodes were positive in 20 patients and negative in 15
patients. Oestrogen receptors (ERs) were positive in 29
patients, and progesterone receptors were positive in 27
patients.
DNA was obtained from frozen tumour tissue containing
60-80% tumour cells. Germline DNA was obtained from
patients' lymphocytes.
Methods
Southern blot analysis DNA was digested with EcoRI and
HindIII restriction enzymes, separated by electrophoresis in
0.8% agarose gel and transferred to nylon membranes, ac-
cording to conventional methods. (Maniatis et al., 1982).
The p16 gene probe used was a 0.96 cDNA probe (kindly
provided by D Beach, Cold Spring Harbor, NY, USA). Blots
were subsequently hybridised to a probe for the actin gene,
situated on chromosome 7, which served as control.
Homozygous deletion of the p16 gene was determined by
visual inspection of the autoradiographs sequentially hyb-
ridised with the p16 and control probe. Suspected
homozygous deletions were more objectively confirmed by
measuring the intensity of hybridisation signals by a den-
sitometer (Densylab, Bioprobe Systems, Montreuil, France).
PCR-SSCP analysis Intronic oligonucleotide primers were
purchased from Bioprobe Systems. The names and nucleotide
sequences of the primers used in this work are listed in Table
I. Two genomic regions were amplified: region 1, encompass-
ing exon 1 and measuring 343 bp; region 2, encompassing
exon 2 and measuring 394 bp. For region 1, we used the
primers published by Kamb et al. (1994). Because SSCP
analysis seems to require fragments of no more than
350-400 bp in length, region 2 was digested, after
amplification and before SSCP analysis, by SmaI enzyme, as
a SmaI restriction site is present in exon 2. This led to two
fragnents, region 2a and region 2b, measuring 162 and 232
bp respectively. For exons 1 and 2, intron-exon boundaries
could be analysed with the primers used, in order to detect
possible splice site mutations.
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Table I Primers used for the PCR of exons 1 and 2 of the p16 gene
DNA fragment amplified Fragment size (bp) Sequence
Region 1 343 2F 5'-GAAGAAAGAGGAGGGGCTG-3'
(containing exon 1) 1108R 5'-GCGCTACCTGATTCCAATTC-3'
Region 2 394 P36 5'-TTCCTTTCCGTCATGCCGG-3'
(containing exon 2) Ml 5'-GTACAAATTCTCAGATCATCAGTCCTC-3'
Genomic DNAs (0.1 tg) were subjected to PCR in 50 gsl of
solution containing 200 tLmol l' each of dATP, dGTP,
dTTP, dCTP, 0.1 of [32P]dCTP (Amersham, UK; 10mCi
ml-'), 25 pmol of 5' and 3' primer 5% dimethylsulphoxide
(DMSO), 10 mmol l- Tris-HCl (pH 9), 50 mmol 1' potas-
sium chloride, 1.5 mmol I` magnesium chloride, Triton X-
100 (0.1%) and gelatin 0.2mg l-', 0.4 units of Taq
polymerase (Appligene, Iillkirch, France) in a thermocycler
(Minicycler, M J Research, Watertown, MA, USA). For
exon 1, PCR was performed as follows: 10 min at 94°C, then
20 cycles of 94'C for 1 min, 64'C for 1 min and 72°C for
1 min with a decrement of 0.2°C per cycle followed by 15
cycles with 94°C for 1 min, 60°C for 1 min, 72°C for 1 min,
then by final elongation at 72°C for 5 min. For exon 2, PCR
was performed as follows: 10 min at 94°C, then 20 cycles of
94°C for 1 min, 56°C for 1 min, 72°C for 1 min, with a
decrement of 0.2°C per cycle, followed by 15 cycles of 94°C
for 1 min, 52°C for 1 min, 72°C for 1 min, followed by final
elongation at 72°C for 5 min. After amplification, 1 jsl of the
reaction mixture for region 1 was mixed with 19 tlI of 0.1%
sodium dodecyl sulphate (SDS), 20 mmol l-l EDTA solution.
For region 2, 1 f.I of the reaction mixture was first digested
by SmaI in 10 l, and diluted in 10 l of SDS-EDTA solu-
tion. Then 3iLl of the diluted region 1 3 tLI and of regions 2a
and 2b were mixed with 3fil of a solution of 95% for-
mamide, 20 mmol 1' EDTA, 0.05% bromophenol blue,
0.05% xylene cyanol, heated 4 min at 80°C and applied (2 tlI
per lane) to a MDE polyacrylamide gel (Bioprobe, France)
containing 90 mmol -' Tris-borate pH 8.3, 4 mmol 1'
EDTA. Electrophoresis was performed at 35 W for 6 h at
room temperature, with cooling using a fan.
Sequencing analysis PCR amplification was performed as
described above, using a biotinylated primer. Single-stranded
DNA template was obtained by binding the biotinylated
PCR products to streptavidin-coupled magnetic beads (Dyn-
abeads, Dynal, Oslo, Norway) and sodium hydroxide de-
naturation according to the manufacturer. Sequencing reac-
tions were performed following the Sequenase 2.0 protocol
(US Biochemicals, Cleveland, OH, USA). The sequencing
primer was the non-biotinylated primer used in PCR. When
ambiguities were present, the opposite strand was sequenced
using the reciprocal combination of biotinylated and non-
biotinylated primers. The sequencing products were analysed
on a 6% polyacrylamide gel containing 7 M urea.
Results and discussion
No homozygous deletion of the p16 gene was found in any
of the 35 patients analysed by Southern blot, confirming the
results obtained by Xu et al. (1994) in five patients. This was
different from results obtained in established breast tumour
cell lines in two studies, in which six of ten and two of five
breast tumours had p16 gene homozygous deletion (Kamb et
al., 1994; Xu et al., 1994). We could however, in the present
study not rule out the presence of heterozygous p16 gene
deletion in some patients. Indeed, in our experience with
Southern blot, demonstrating loss of one copy of a gene in
tumour cells contaminated by up to 30% or even 40% of
normal residual cells is difficult, even if one compares the
intensity of hybridisation signals using a densitometer
(Quesnel et al., 1995).
PCR-SSCP analysis of exons 1 and 2 of the p16 gene
(which cover 97% of the coding sequence) was performed in
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Figure 1 (a) SSCP analysis of exon 2 of the p16 gene, after
digestion with SmaI enzyme. Abnormal bands were seen in addi-
tion to normal bands in sample T 351 (tumour sample from
patient no. 351), but not in sample L 351 (blood lymphocytes
from the same patient) and in other samples (tumour samples
from other patients). (b) Direct sequencing of exon 2 of the p16
gene in sample T 351, showing a missense mutation at codon 52
(ATG-AAG) leading to an amino acid substitution (Met-+
Lys).
33 of the cases analysed by Southern blot. Normal
PCR-SSCP findings were observed in all 33 patients for
exon 1 and in 32 cases for exon 2, by comparison with
controls. The remaining patient had an abnormal SSCP
profile for exon 2 (Figure la). Direct sequencing of exon 2
showed a missense point mutation at codon 52 (ATG-*
AAG), leading to an amino acid substitution (Met-*Lys)
(Figure lb). This mutation of p16, to our knowledge, had
not previously been reported in tumours. Normal wild-type
bands were still present on SSCP and sequencing gel. It could
not be concluded from this analysis whether they corres-
ponded to the persistence of a normal p16 allele in tumour
cells or to the contamination of tumour tissue by stroma
cells. The clinical stage of disease in this patient was
T2NOMO, and the oestrogen and progesterone receptor status
was positive. SSCP findings for exon 2 of the p16 gene were
normal in this patient's lymphocytes. This demonstrated that
the codon 52 mutation was not a polymorphism. Further-
more, because it led to an amino acid substitution, this
mutation could have potentially been associated with a
modification of the protein's function. However, as we found
only one point mutation in 33 patients, and as Xu et al.
(1994) found no mutation in 37 patients (and also in five
established breast tumour cell lines), p16 point mutations
must be very rare in breast carcinoma. Overall, these findings
suggest that p16 gene alterations play a minor role, if any, in
the pathogenesis or progression of breast carcinoma. They
also stress the disparity between data obtained in established
cell lines and primary tumour specimens, which had
previously been observed for other genes. On the other hand,
only eight of our patients were oestrogen receptor (ER)
negative, whereas ER status was not known in the report of
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Xu et al. (1994). Analysis of p16 alterations in a larger
number of ER-negative breast carcinomas (i.e. high-risk
patients) is therefore required before any conclusion can be
made. Finally, some oesophageal, liver, lung and colon
cancer cell lines with normal p16 gene coding sequence but
absent p16 protein have recently been reported (Okamoto et
al., 1994), and analysis of p16 protein expression will also
have to be made in breast carcinoma.
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